HFB-200301 is an IgG1 antibody that targets the tumor necrosis factor receptor 2 (TNFR2). In the presence of sTNF, HFB-200301 enhances the activation of TNFR2, which then stimulates related signaling pathways, such as the activation of NF-κB dimers through the classical NF-κB pathway, influencing cell metabolism and gene expression. HFB-200301 shows potential for cancer research.